Jul. 30 at 1:52 AM
Johnson & Johnson announced a strategic partnership with private biotech company Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, while securing an exclusive option to acquire the company for up to
$2.58 billion.
Under the agreement, J&J will make
$785 million in upfront payments, including a
$465 million equity investment, plus up to
$140 million in milestone-based payments. The collaboration focuses on Sail’s in vivo CAR-T platform, which reprograms immune cells directly inside the patient’s body, potentially offering a simpler and more scalable alternative to traditional cell therapies.
If J&J exercises its acquisition option, it would pay an additional
$2.58 billion. The deal expands the company’s capabilities beyond its existing oncology cell-therapy franchise and strengthens its immunology pipeline. J&J expects the transaction, if completed, to reduce adjusted EPS by approximately
$0.18 in 2026 and
$1.28 in 2027.
$JNJ